International Journal of Cancer最新文献_第3页

Current and future burden of female breast cancer in the Middle East and North Africa region using estimates from GLOBOCAN 2022.

IF 5.7 2区医学

International Journal of Cancer Pub Date : 2025-01-10 DOI: 10.1002/ijc.35325

Mariam Zahwe, Karima Bendahhou, Sultan Eser, Deborah Mukherji, Heba Fouad, Ibtihal Fadhil, Isabelle Soerjomataram, Ariana Znaor

{"title":"Current and future burden of female breast cancer in the Middle East and North Africa region using estimates from GLOBOCAN 2022.","authors":"Mariam Zahwe, Karima Bendahhou, Sultan Eser, Deborah Mukherji, Heba Fouad, Ibtihal Fadhil, Isabelle Soerjomataram, Ariana Znaor","doi":"10.1002/ijc.35325","DOIUrl":"https://doi.org/10.1002/ijc.35325","url":null,"abstract":"Breast cancer is the most diagnosed female cancer and the most common cause of cancer death in women in the Middle East and North Africa (MENA) region. In this study, we aimed to describe the current patterns of breast cancer among women in the MENA region and estimate the burden for the year 2050. We used the estimates of the breast cancer incidence and mortality from the GLOBOCAN 2022 database and predicted the burden of breast cancer in 2050 according to different scenarios. With 118,200 new breast cancer cases and 41,000 deaths, breast cancer contributed to 25% of cancer incidence and almost 20% of cancer mortality among women in MENA. The highest incidence rates were in Algeria and Iraq (≥60/100,000) and the lowest rates in Saudi Arabia and Yemen (<30/100,000). The highest mortality rates were in Iraq, Syrian Arab Republic, Algeria, and Sudan (>20/100,000), and the lowest in Saudi Arabia (7.6/100,000). While the incidence rates were low compared to other world regions, the mortality rates (16.9/100,000) were higher than in any other world region except Sub-Saharan Africa. The incidence rates for women <50 years in MENA were 5.5 times lower than in women aged ≥50 years, and lower than for women <50 years in Western countries. By 2050, the burden of breast cancer is estimated to increase to 219,000 new cases and to 88,900 deaths (86% and 117%, respectively). Scaling up cancer control to curb the rising burden alongside improved surveillance is vital to develop targeted interventions and improving outcomes.","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142941814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Considerations to forgo systemic treatment in patients with advanced esophageal or gastric cancer: A real-world evidence study.

IF 5.7 2区医学

International Journal of Cancer Pub Date : 2025-01-09 DOI: 10.1002/ijc.35314

Ellis Slotman, Marieke Pape, Hanneke W M van Laarhoven, Roos E Pouw, Yvette M van der Linden, Rob H A Verhoeven, Sabine Siesling, Heidi P Fransen, Natasja J H Raijmakers

{"title":"Considerations to forgo systemic treatment in patients with advanced esophageal or gastric cancer: A real-world evidence study.","authors":"Ellis Slotman, Marieke Pape, Hanneke W M van Laarhoven, Roos E Pouw, Yvette M van der Linden, Rob H A Verhoeven, Sabine Siesling, Heidi P Fransen, Natasja J H Raijmakers","doi":"10.1002/ijc.35314","DOIUrl":"https://doi.org/10.1002/ijc.35314","url":null,"abstract":"The majority of patients with advanced esophageal or gastric cancer do not start palliative systemic treatment. To gain insight into the considerations underlying the decision not to start systemic treatment, we analyzed characteristics of patients starting and not starting systemic treatment, reasons for not starting systemic treatment, and receipt of local palliative treatments on a nationwide scale. Patients diagnosed with advanced esophageal or gastric cancer between 2015 and 2021 were included (n = 10,948). Survival was compared using propensity score matching on patient and disease characteristics. Most patients did not start systemic treatment (esophageal cancer 59%; gastric cancer 64%). These patients were generally older, more often female, had more comorbidities and a worse performance status. The main reason for not starting systemic treatment was patient or family preference (35%). Among patients who did not start systemic treatment, 47% (esophageal) and 19% (gastric), received local palliative treatment, most commonly radiotherapy. Patients who did not start systemic treatment had worse median overall survival compared to patients who did start (esophageal cancer 2.9 months vs. 8.9 months; gastric cancer 2.2 vs. 8.2 months). These findings indicate that patient condition and disease burden are important aspects in systemic treatment decisions. However, patient or family preference was the main reason for not starting systemic treatment, highlighting that their priorities also strongly influence the decision. Systemic treatment did show to be associated with improved overall survival in matched patients, and therefore adequately weighing treatment risks and benefits based on real world data against patient preferences is of utmost importance.","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142941812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Estrogen, estrogen receptor and the tumor microenvironment of NSCLC.

IF 5.7 2区医学

International Journal of Cancer Pub Date : 2025-01-03 DOI: 10.1002/ijc.35309

Mingxin Diao, Yangwei Wang, Shihao Wu, Shiwen He, Yongde Liao

{"title":"Estrogen, estrogen receptor and the tumor microenvironment of NSCLC.","authors":"Mingxin Diao, Yangwei Wang, Shihao Wu, Shiwen He, Yongde Liao","doi":"10.1002/ijc.35309","DOIUrl":"https://doi.org/10.1002/ijc.35309","url":null,"abstract":"Lung cancer remains the foremost cause of cancer-related mortality worldwide. Clinical observations reveal a notable increase in both the proportion and mortality rate among female non-small cell lung cancer (NSCLC) patients compared to males, a trend that continues to escalate. Extensive preclinical research underscores the pivotal role of estrogen in the initiation, progression, prognosis, and treatment response of NSCLC. Estrogen receptors are widely expressed in stromal and immune cells, influencing cellular activities across innate and adaptive immune systems. Immune evasion mechanisms significantly impact tumor development and outcomes, with immunotherapy offering promise in NSCLC by targeting these mechanisms. The intriguing gender disparities in immunotherapy responses prompt an exploration into the data on NSCLC occurrence, progression, and gender-specific immunotherapy. Evidence highlights estrogen's contribution to a tumor-permissive microenvironment, influencing various cells including cancer-associated fibroblasts, macrophages, neutrophils, dendritic cells, natural killer cells, B cells, and T cells. Gender-specific variations in NSCLC occurrence, development, prognosis, and treatment efficacy likely stem from interactions between estrogen, lung cancer cells, and these estrogen-responsive cells, shaping a microenvironment conducive to tumor progression. Clarifying estrogen's role and its signaling pathways in NSCLC may unveil novel therapeutic strategies to modify the tumor microenvironment or enhance immunotherapy efficacy.","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142925941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neo-enhancers in T-cell acute lymphoblastic Leukaemia (T-ALL) and beyond.

IF 5.7 2区医学

International Journal of Cancer Pub Date : 2025-01-03 DOI: 10.1002/ijc.35315

Charlotte Smith, Vahid Asnafi, Aurore Touzart

引用次数: 0

Curvilinear incidence models for parity in the entire fertility range for cancers of the breast, ovary, and endometrium: A follow-up of the Norwegian 1960 Census.

IF 5.7 2区医学

International Journal of Cancer Pub Date : 2025-01-03 DOI: 10.1002/ijc.35312

Eiliv Lund, Lill-Tove Rasmussen Busund, Lars Holden

{"title":"Curvilinear incidence models for parity in the entire fertility range for cancers of the breast, ovary, and endometrium: A follow-up of the Norwegian 1960 Census.","authors":"Eiliv Lund, Lill-Tove Rasmussen Busund, Lars Holden","doi":"10.1002/ijc.35312","DOIUrl":"https://doi.org/10.1002/ijc.35312","url":null,"abstract":"The protective effect of parity has been demonstrated for cancer of the breast, ovary, and endometrium but no studies have estimated the effect of each subsequent birth in women with 10 or more children or grand-grand parity women, nor compared the linear relationship of the three cancers sites. Here, we aim to explore these relationships based on the Norwegian 1960 Census. The question of parity in present marriage was answered by 385,816 women born 1870-1915, a period with high fertility. Age at marriage has been validated as a proxy for age at first birth AFB. With high parity age at first birth will logically be restricted to early births giving structural zeros. Follow-up was based on linkages to national registers until the first of any of the three diagnoses, death, or age 90 before 31.12.2005. Included were 16,905 breast cancers, 3827 ovarian cancers, and 3834 endometrial cancers. Age- and period-specific incidence rates based on person-years, PY, were used in logit regression models. The percentage decrease for each additional child over the total parity range was for breast cancer 10.5% (95% CI; 9.6-11.4), ovarian cancer 13.2% (11.2-15.3), and endometrial cancer 10.9% (8.9-12.8), in a model without higher order terms. Adjustment for structural zeros reduced the effect of age at first birth to less than one additional child. To the best of our knowledge this is the first analysis of the curvilinear relationships for cancers of the breast, ovary, and endometrium throughout the extended fertility range.","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142918832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Potential for enhancing efficacy of screening colonoscopy by lowering starting ages and extending screening intervals: A modelling study for Germany.

IF 5.7 2区医学

International Journal of Cancer Pub Date : 2025-01-03 DOI: 10.1002/ijc.35322

Dmitry Sergeev, Thomas Heisser, Michael Hoffmeister, Hermann Brenner

{"title":"Potential for enhancing efficacy of screening colonoscopy by lowering starting ages and extending screening intervals: A modelling study for Germany.","authors":"Dmitry Sergeev, Thomas Heisser, Michael Hoffmeister, Hermann Brenner","doi":"10.1002/ijc.35322","DOIUrl":"https://doi.org/10.1002/ijc.35322","url":null,"abstract":"Studies aimed to evaluate the expected impact of alternative screening strategies are essential for optimizing colorectal cancer (CRC) screening offers, but such studies are lacking in Germany, where two screening colonoscopies (CS) 10 years apart are offered for men from age 50 and women from age 55. Our aim was to explore whether and to what extent the efficacy of utilizing two CS could be enhanced by alternative starting ages and screening intervals. We modeled the expected numbers of CRC cases, CRC deaths, years of potential life lost (YPLL), and disability-adjusted life years (DALYs) due to CRC in hypothetical cohorts of 100,000 men and women aged 45-85 using COSIMO, a validated Markov-based multi-state simulation model. Modeled strategies included combinations of starting ages (45/50/55/60) and CS (10/15/20 years). For men, CRC deaths could be slightly reduced by extending the interval to 15 years, with a second CS at 65. YPLL and DALYs would be reduced by decreasing starting age to 45 when combined with a 15-year screening interval. For women, use of two CS at ages 50 and 65 would reduce all CRC burden parameters compared to the current earliest-use offer at 55 and 65 years. Our results suggest that lowering the starting age of screening colonoscopy to 45 for men and 50 for women, combined with extending the CS screening interval to 15 years would have the potential to enable significant reductions in years of potential life lost, and disability-adjusted life years compared to current screening offers in Germany.","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142918834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction to "Differences in the incidence and mortality of digestive cancer between Global Cancer Observatory 2020 and Global Burden of Disease 2019".

IF 5.7 2区医学

International Journal of Cancer Pub Date : 2024-12-31 DOI: 10.1002/ijc.35324

引用次数: 0

Adiposity and risks of gastrointestinal cancers: A 10-year prospective study of 0.5 million Chinese adults.

IF 5.7 2区医学

International Journal of Cancer Pub Date : 2024-12-31 DOI: 10.1002/ijc.35303

Wing Ching Chan, Iona Millwood, Christiana Kartsonaki, Huaidong Du, Daniel Schmidt, Rebecca Stevens, Junshi Chen, Pei Pei, Canqing Yu, Dianjianyi Sun, Jun Lv, Xianyong Han, Liming Li, Zhengming Chen, Ling Yang

{"title":"Adiposity and risks of gastrointestinal cancers: A 10-year prospective study of 0.5 million Chinese adults.","authors":"Wing Ching Chan, Iona Millwood, Christiana Kartsonaki, Huaidong Du, Daniel Schmidt, Rebecca Stevens, Junshi Chen, Pei Pei, Canqing Yu, Dianjianyi Sun, Jun Lv, Xianyong Han, Liming Li, Zhengming Chen, Ling Yang","doi":"10.1002/ijc.35303","DOIUrl":"https://doi.org/10.1002/ijc.35303","url":null,"abstract":"Associations of adiposity with risks of oesophageal squamous cell carcinoma (ESCC) and non-cardia stomach cancer, both prevalent in China, are still inconclusive. While adiposity is an established risk factor for colorectal cancer, the relevance of fat-free mass and early-adulthood adiposity remains to be explored. The prospective China Kadoorie Biobank study included 0.5 million adults (aged 30-79 years) from 10 areas in China. Participants' body size and composition were measured at baseline and at resurveys (amongst a subset). After >10 years of follow-up, 2350, 3345 and 3059 incident cases of oesophageal (EC), stomach (SC) and colorectal (CRC) cancers were recorded, respectively. Cox regression was used to estimate hazard ratios (HRs) for these cancers in relation to different adiposity traits. General and central adiposity were inversely associated with EC (primarily ESCC) risk, with HRs of 0.81 (95% CI 0.77-0.85), 0.76 (0.72-0.81) and 0.87 (0.83-0.92) per SD increase in usual levels of BMI, body fat percentage (BF%) and waist circumference (WC), respectively. Adiposity was also inversely associated with SC risk [HR = 0.79 (0.75-0.83) and 0.88 (0.84-0.92) per SD increase in usual BF% and WC], with heterogeneity by cardia and non-cardia subsites, and positively associated with CRC [HR = 1.09 (1.03-1.15) and 1.17 (1.12-1.22) per SD higher usual BF% and WC]. Fat-free mass was inversely associated with EC [HR = 0.93 (0.89-0.98) per SD increase] but positively associated with CRC [1.09 (1.04-1.14)], while BMI at age 25 was positively associated with all three cancers. After mutual adjustment, general adiposity remained inversely associated with EC and SC, while central adiposity remained positively associated with CRC.","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142906287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Life expectancy in rare histological prostate cancer subtypes.

IF 5.7 2区医学

International Journal of Cancer Pub Date : 2024-12-30 DOI: 10.1002/ijc.35323

Carolin Siech, Mario de Angelis, Letizia Maria Ippolita Jannello, Francesco Di Bello, Natali Rodriguez Peñaranda, Jordan A Goyal, Zhe Tian, Fred Saad, Shahrokh F Shariat, Stefano Puliatti, Nicola Longo, Ottavio de Cobelli, Alberto Briganti, Mike Wenzel, Philipp Mandel, Luis A Kluth, Felix K H Chun, Pierre I Karakiewicz

{"title":"Life expectancy in rare histological prostate cancer subtypes.","authors":"Carolin Siech, Mario de Angelis, Letizia Maria Ippolita Jannello, Francesco Di Bello, Natali Rodriguez Peñaranda, Jordan A Goyal, Zhe Tian, Fred Saad, Shahrokh F Shariat, Stefano Puliatti, Nicola Longo, Ottavio de Cobelli, Alberto Briganti, Mike Wenzel, Philipp Mandel, Luis A Kluth, Felix K H Chun, Pierre I Karakiewicz","doi":"10.1002/ijc.35323","DOIUrl":"https://doi.org/10.1002/ijc.35323","url":null,"abstract":"Survival differences in rare histological prostate cancer (PCa) subtypes relative to age-matched population-based controls are unknown. Within Surveillance, Epidemiology, and End Results database (2004-2020), newly diagnosed (2004-2015) PCa patients were identified. Relying on the Social Security Administration Life Tables (2004-2020) with 5 years of follow-up, age-matched population-based controls (Monte Carlo simulation) were simulated for each patient. Kaplan-Meier analyses addressed survival rates. Of 582,220 patients, 580,368 (99.68%) harbored acinar, 867 (0.15%) ductal, 534 (0.09%) neuroendocrine, 368 (0.07%) mucinous, and 83 (0.01%) signet ring cell carcinoma. The metastatic stage was most prevalent in neuroendocrine (62%). In the localized stage, the overall survival difference at 5 years of follow-up was greatest in neuroendocrine (22% vs. 72%), signet ring cell (78% vs. 84%), and ductal carcinoma (71% vs. 77%). In the locally advanced stage, overall survival difference was greatest in neuroendocrine (16% vs. 79%), signet ring cell (75% vs. 91%), ductal (78% vs. 84%), and mucinous carcinoma (84% vs. 90%). In the metastatic stage, the overall survival difference was greatest in neuroendocrine (3% vs. 81%), mucinous (26% vs. 84%), and acinar carcinoma (27% vs. 85%). Regardless of stage, neuroendocrine carcinoma patients exhibit the least favorable life expectancy compared with population-based controls. Conversely, all other rare histological PCa subtypes do not meaningfully affect life expectancy in localized or locally advanced stages, except for locally advanced signet ring cell adenocarcinoma.","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142908716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessing the performance of chest x-ray screening in detecting early-stage lung cancer in the general population.

IF 5.7 2区医学

International Journal of Cancer Pub Date : 2024-12-30 DOI: 10.1002/ijc.35316

Choy-Lye Chei, Sho Nakamura, Kaname Watanabe, Takashi Mizutani, Hiroto Narimatsu

{"title":"Assessing the performance of chest x-ray screening in detecting early-stage lung cancer in the general population.","authors":"Choy-Lye Chei, Sho Nakamura, Kaname Watanabe, Takashi Mizutani, Hiroto Narimatsu","doi":"10.1002/ijc.35316","DOIUrl":"https://doi.org/10.1002/ijc.35316","url":null,"abstract":"Chest x-ray (CXR) is widely used for lung cancer screening in Japan. We evaluated the sensitivity and specificity of CXR in detecting early lung cancer and its histological types. We cross-referenced lung cancer municipality screening data with the regional cancer registry database. The results of individuals screened at least once from 2016 to 2018 were utilized to calculate CXR's sensitivity and specificity for lung cancer diagnosed within 1 year of screening (n = 161,251) by stage and its histological types. We stratified analyses based on sex, age, smoking status, first screening, and screening intervals. CXR's sensitivity and specificity for early-stage lung cancer were 73.6% (95% confidence interval [CI], 66.8-79.6) and 94.1% (95% CI, 94.0-94.2), respectively. No significant differences were found in sex or smoking status. The sensitivity for early-stage adenocarcinoma was 76.0% (95% CI, 68.3-82.7), which was higher than that for early-stage squamous cell carcinoma (70.4% [95% CI, 67.3-86.0]). However, no significant differences were observed (p = .532). No significant differences were found in sex or smoking status for early-stage adenocarcinoma or early-stage squamous cell carcinoma. Due to its moderate sensitivity and high specificity, CXR could be a useful tool for mass screening in the general population. However, because CXR failed to detect 26.4% of early-stage cases, practitioners should inform high-risk patients of other screening options.","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142908693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0